+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 42 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are studying adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP to understand why they choose certain treatments, particularly switching to HyQvia, and how satisfied they are with HyQvia and their previous therapies. The study also explores how CIDP affects work productivity and daily activities, as well as the signs and symptoms of CIDP. The research collects information on medical problems or side effects during HyQvia treatment, its effectiveness, and healthcare needs such as emergency or hospital visits. Participants are divided into two groups those who plan to switch to HyQvia within six weeks after joining the study and those who have already switched within six weeks before joining. Data will be collected over 12 months through interviews, medical record reviews, and questionnaires. Treatment follows the doctors usual clinical care and is not controlled by the study. During the study, participants will complete questionnaires about their treatment preferences, satisfaction, quality of life, disability, and work productivity at the start and throughout the 12 months. Researchers will monitor any adverse effects and changes in physical strength and disability scores. Healthcare use and treatment details will be tracked regularly to understand the real-world use and impact of HyQvia in managing CIDP.

Age: 18Years +All Genders
15 locations
G

Actively Recruiting

Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.

Age: 18Years +All GendersPhase 3
317 locations
C

Actively Recruiting

Researchers are evaluating empasiprubart compared to intravenous immunoglobulin IVIg for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP. This Phase 3 study aims to assess the effectiveness and safety of these treatments in people who have responded to IVIg in the past and currently have active disease with residual disability. The study has two parts. In Part A, lasting 24 weeks, participants receive either empasiprubart plus a placebo resembling IVIg or IVIg plus a placebo resembling empasiprubart. After Part A, all participants enter Part B, a 96-week period where they receive empasiprubart without IVIg. Some participants also receive a placebo to maintain the blinding during Part A. Participants will be monitored through various assessments including changes in disability scores, grip strength, and quality of life measures at baseline and throughout the study periods. Researchers will also track adverse events, antibody formation against empasiprubart, and serum drug levels. Total participation spans approximately 120 weeks, including both study parts and ongoing evaluations.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are evaluating empasiprubart for adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition causing nerve inflammation and muscle weakness. This Phase 3 randomized, double-blinded, placebo-controlled study aims to demonstrate the efficacy and safety of empasiprubart in treating CIDP. The study is sponsored by argenx and includes adults diagnosed with typical or variant forms of CIDP who have active disease and residual disability. Participants are randomly assigned in part A to receive either empasiprubart or a placebo by intravenous infusion for 24 weeks 6 months. After part A, all participants enter part B, where everyone receives empasiprubart for 96 weeks 24 months. Participants who received empasiprubart in part A will receive a placebo infusion once during part B to maintain blinding. Throughout the study, participants will undergo regular assessments including the adjusted Inflammatory Neuropathy Cause and Treatment aINCAT score, grip strength measurements, muscle strength evaluations, and quality of life questionnaires. Researchers will monitor changes from baseline in motor function, disability, and symptom severity up to 24 weeks in part A and continue evaluations through part B. Safety measures include tracking adverse events and immune responses. The total participation duration can last up to 120 weeks approximately 30 months.

Age: 18Years +All GendersPhase 3
89 locations
P

Actively Recruiting

Researchers are evaluating how well adults with new-onset generalized myasthenia gravis gMG respond to treatment with efgartigimod PH20 SC. This study focuses on adults who have had generalized disease signs or symptoms for less than one year and aims to assess clinical outcomes during a phase 4, open-label, single-group trial. Participants will receive subcutaneous injections of efgartigimod PH20 SC during a treatment period lasting 51 weeks. The study follows each participant for approximately 58 weeks to monitor their response to the treatment and any changes in their condition over time. During the study, participants will be regularly evaluated using measures like the proportion who achieve minimal symptom expression MSE within the first 16 weeks, changes in MG-ADL and MG-QOL-15r scores over time, and use of systemic corticosteroids as add-on therapy. Researchers will also monitor the incidence of adverse events throughout the study period to assess safety and tolerability.

Age: 18Years +All GendersPhase 4
18 locations
E

Actively Recruiting

Researchers are evaluating whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G IgG in the blood over time compared to Gamunex-C, which is given into a vein once every three weeks in people with chronic inflammatory demyelinating polyradiculoneuropathy CIDP. This Phase 3 study focuses on measuring steady-state IgG levels to understand the pharmacokinetics and safety of these treatments in participants with CIDP. Participants will first undergo up to 28 days of screening to confirm eligibility. Qualified participants then start a 19-week intravenous treatment period receiving Gamunex-C every three weeks for seven doses. About one week after the last Gamunex-C dose, participants enter a 16-week subcutaneous treatment period with XEMBIFY, receiving weekly doses for a total of 16 doses. Blood samples are collected during both treatment phases to measure IgG levels. Throughout the study, participants will have regular blood tests to monitor IgG concentrations and assess treatment effects. The main outcomes include measuring the area under the concentration-time curve AUC of IgG during both intravenous and subcutaneous dosing intervals. The study monitors safety and collects data until the end of the 35-week treatment period, providing detailed information on how these treatments perform over time in people with CIDP.

Age: 18Years +All GendersPhase 3
15 locations
E

Actively Recruiting

Researchers are evaluating how the study medicine PF-06823859 dazukibart works in adults with active idiopathic inflammatory myopathies, specifically dermatomyositis DM and polymyositis PM. These rare diseases cause muscle inflammation leading to muscle weakness and sometimes skin rash in DM. The study aims to assess the safety and effectiveness of dazukibart compared to placebo in people already receiving stable doses of corticosteroids or immunosuppressants. Participants will be randomly assigned to receive either dazukibart or a placebo via intravenous infusion every 4 weeks, starting from Day 1 to Week 48. Each infusion takes about 1 hour and is administered at the study site. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo, allowing for an unbiased comparison. Participants will be involved in approximately 15 visits over about 13 months. During these visits, researchers will monitor muscle strength, skin symptoms, physical function, fatigue, itch severity, corticosteroid use, and overall improvement using various clinical scales and patient questionnaires. Safety will be closely followed throughout the study. The main outcome measure is the Total Improvement Score TIS evaluated at 24 weeks outside the US and 52 weeks within the US.

Age: 18Years +All GendersPhase 3
138 locations
C

Actively Recruiting

Researchers are evaluating an experimental drug combination of fianlimab and cemiplimab compared to the approved combination of relatlimab and nivolumab in adults with unresectable or metastatic melanoma, a serious skin cancer. The study aims to assess the safety and effectiveness of these treatments, including side effects and how the body responds to the drugs. It is a phase 3 clinical trial designed to compare these regimens directly. Participants receive intravenous doses of either fianlimab plus cemiplimab every 3 weeks or relatlimab plus nivolumab every 4 weeks. The study randomly assigns patients to one of these two treatment groups. Treatment continues while monitoring for response and side effects, with the study lasting up to 72 months for assessing outcomes. During the trial, participants undergo regular evaluations including scans to measure tumor response, blood tests to monitor drug levels and antibodies against the drugs, and assessments of side effects. Researchers collect data on overall survival, disease control, and safety throughout the study period. Follow-up and monitoring may continue for several years to fully understand the treatments impacts.

Age: 18Years +All GendersPhase 3
113 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations

1-10 of 42

1